Cartilage repair

Stem cells from cord blood and tissue biopsies are being investigated as possible treatments for cartilage repair. Click on the link provided to find out more about each trial. It remains too early to know which approach will be most suitable. We need evidence collected in clinical trials to determine if a proposed stem cell treatment is both safe and effective.

tagged as Cartilage repair

  • Follow-Up Study of CARTISTEM┬« Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect Location: South Korea
    Overview: This trial aims to investigate whether CARTISTEM® can assist in the repair of cartilage damage in the knee compared to standard treatment. CARTISTEM® is a proprietary product of mesenchymal stem cell made from donated human umbilical cord blood. The study is being conducted in conjunction with biotech firms MEDIPOST Co Ltd and Dong A Pharmaceuticals at 10 major teaching hospitals and medical centres in South Korea. Participants will either receive CARTISTEM® (experimental group) or standard treatment (microfracture). Participants will be monitored for complications and changes in their condition for five years post-treatment. The study aims to enrol 103 subjects and is expected to be completed by May 2015.
    Link to Clinical Registry
    Trial Design: Observational Study
    Status: Not yet started
    Stem Cell: Umbilical Cord Stem Cells
  • Transplantation of a Scaffold-free Tissue Engineered Construct Derived from Autologous Synovial Mesenchymal Stem Cells for Cartilage Repair Location: Japan
    Overview: This trial aims to assess the benefit of implanting a product made from the patient's own mesenchymal stem cells for cartilage repair. The study is being conducted by the Osaka University Medical School and the Osaka Hospital Medical Centre for Translational Research and proposes to enrol six patients from September 2012. For each participant, a product will be made from their own mesenchymal stem cells that will then be introduced to the fluid surrounding the joint. Participants will be monitored for complications and changes in clinical condition, including evidence of cartilage repair.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Stem Cells (unspecified)
  • Evaluation of Safety and Exploratory Efficacy of CARTISTEM┬«, a Cell Therapy Product for Articular Cartilage Defects Location: US
    Overview: This trial aims to evaluate the use of a proprietary product made from umbilical cord blood derived (Cartistem™) in treating cartilage damage. The trial is sponsored by a biotechnology company MediPost Co Ltd and is being conducted at two centres in the US - the Rush University Medical Centre in Chicago and the Brigham & Women's Hospital in Massachusetts. The trial proposes to recruit 15 patients from November 2012 and January 2015. Participants will receive a single injection of Cartistem™ directly into the knee. Cartistem™ has been prepared from donated umbilical cord where the mesenchymal stem cells have been expanded in the laboratory. blood derived stem cell in combination with hyaluronic acid preparation (in treating full thickness, focal cartilage defects of the knee resulting from trauma, ageing or degenerative diseases. Participants will be monitored for complications and changes in clinical condition over the next 24 months, including the degree of cartilage regeneration and morphological constitution of the repaired cartilage as assessed using MRI.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Umbilical Cord Stem Cells
  • Intra-articular mesenchymal stem cell injections following arthroscopic microfracture versus arthroscopic microfracture alone for knee cartilage defects: a pilot randomised controlled trial Location: Australia
    Overview:

    This Phase II study seeks to determine the effectiveness of using the patient’s own adipose-derived mesenchymal stem cell to repair cartilage defects. 40 participants will be recruited. Half will have arthroscopic microfracture and mesenchymal stem cells administered weekly for up to 13 weeks post surgery, while the other half will have arthroscopic microfracture alone.

    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Adult Fatty Tissue Stem Cells